EBR Systems, Inc. (EBRCZ)

OTCMKTS · Delayed Price · Currency is USD
0.3700
-0.0020 (-0.54%)
At close: May 22, 2026
Market Cap157.37M -43.8%
Revenue (ttm)3.98M
Net Income-55.28M
EPS-0.13
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,000
Average Volume6,231
Open0.3700
Previous Close0.3720
Day's Range0.3700 - 0.3700
52-Week Range0.3700 - 1.5000
Beta0.59
RSI38.90
Earnings DateAug 12, 2026

About EBR Systems

EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. The company offers WiSE cardiac resynchronization therapy system that uses a proprietary wireless technology to deliver pacing stimulation directly to the inside of the left ventricle of the heart. Its products are used to eliminate lead complications, such as placement difficulty, unintended nerve stimulation, dislodgement, extraction, and repositioning. The company was incorporated in 2003 and is based in Sunnyvale, California. [Read more]

Sector Healthcare
Founded 2003
Employees 135
Stock Exchange OTCMKTS
Ticker Symbol EBRCZ
Full Company Profile

Financial Performance

Financial Statements

News

EBR Systems Earnings Call Transcript: Q1 2026

Q1 revenue surged to $2.4 million from zero year-over-year, driven by strong physician engagement and expanding hospital adoption. Investments in sales and manufacturing are fueling growth, with a new facility and major hospital contracts supporting long-term scale.

9 days ago - Transcripts

EBR Systems Earnings release: Q1 2026

EBR Systems released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.

9 days ago - Filings

EBR Systems Transcript: AGM 2026

The meeting highlighted a milestone year with FDA approval, reimbursement wins, and strong commercial progress. All board and compensation proposals were supported, and financial statements were presented with no questions raised.

24 days ago - Transcripts

EBR Systems Slides: FY 2026

EBR Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 28, 2026.

24 days ago - Filings

EBR Systems Earnings Call Transcript: Q4 2025

FDA approval and commercial rollout of leadless left ventricular pacing drove strong Q4 growth, with revenue over $900,000 and patient volume doubling sequentially. High physician engagement, robust reimbursement, and no direct competitors support continued expansion, while a new manufacturing facility and vertical integration are underway.

2 months ago - Transcripts

EBR Systems Annual report: Q4 2025

EBR Systems has published its Q4 2025 annual report on March 19, 2026.

2 months ago - Filings

EBR Systems Earnings release: Q4 2025

EBR Systems released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.

2 months ago - Filings

EBR Systems Transcript: EGM 2026

Two key proposals were presented: a reverse stock split at a flexible ratio and ratification of securities issued in May 2025. Voting was conducted by poll, with results to be published on the ASX and company website.

2 months ago - Transcripts

EBR Systems Slides: Investor presentation

EBR Systems has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.

2 months ago - Filings

EBR Systems Transcript: EGM 2026

The meeting focused on a proposal to consolidate common shares, freeing up authorized shares for future financing and strategic flexibility. Shareholders were assured that CDI holdings and value would not be affected, and no immediate plans for capital raising or U.S. listing were disclosed.

4 months ago - Transcripts

EBR Systems Slides: FY 2026

EBR Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on January 20, 2026.

4 months ago - Filings

EBR Systems Transcript: 44th Annual J.P. Morgan Healthcare Conference

A unique leadless pacemaker for left ventricular pacing has launched with FDA approval and strong reimbursement, targeting a $5.8B U.S. market. Early adoption is on track, with modular compatibility enabling new therapies and a disciplined commercial rollout supporting growth.

4 months ago - Transcripts

EBR Systems Earnings release: Q3 2025

EBR Systems released its Q3 2025 earnings on November 11, 2025, summarizing the period's financial results.

6 months ago - Filings

EBR Systems Earnings release: Q2 2025

EBR Systems released its Q2 2025 earnings on August 12, 2025, summarizing the period's financial results.

10 months ago - Filings

EBR Systems Slides: Capital Raising Presentation

EBR Systems has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2025.

1 year ago - Filings

EBR Systems Transcript: AGM 2025

The meeting highlighted a pivotal year marked by FDA approval, commercial readiness, and strategic expansion plans. Shareholders voted on director reelections, equity plans, and option grants, with results to be published. Financial statements and audit matters were also addressed.

1 year ago - Transcripts

EBR Systems Slides: FY 2025

EBR Systems has posted slides in relation to its FY 2025 quarterly earnings report, which was published on May 21, 2025.

1 year ago - Filings